Cellectis SA (CLLS) - Total Liabilities
Based on the latest financial reports, Cellectis SA (CLLS) has total liabilities worth $229.27 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CLLS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Cellectis SA - Total Liabilities Trend (2007–2025)
This chart illustrates how Cellectis SA's total liabilities have evolved over time, based on quarterly financial data. See Cellectis SA free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Cellectis SA Competitors by Total Liabilities
The table below lists competitors of Cellectis SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indomobil Sukses Internasional
JK:IMAS
|
Indonesia | Rp64.50 Trillion |
|
HomeToGo SE
XETRA:HTG
|
Germany | €387.58 Million |
|
Citizens Community Bancorp Inc
NASDAQ:CZWI
|
USA | $1.59 Billion |
|
KOSKISEN OYJ EO 1
F:EZ8
|
Germany | €158.72 Million |
|
Export Inv
TA:EXPO
|
Israel | ILA21.88 Billion |
|
Legal & General Group PLC
LSE:LGEN
|
UK | GBX579.96 Billion |
|
A Paradise Acquisition Corp.
NASDAQ:APAD
|
USA | $8.47 Million |
|
Jakarta Setiabudi Internasional
JK:JSPT
|
Indonesia | Rp3.30 Trillion |
Liability Composition Analysis (2007–2025)
This chart breaks down Cellectis SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CLLS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis SA (2007–2025)
The table below shows the annual total liabilities of Cellectis SA from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $248.82 Million | -1.46% |
| 2024-12-31 | $252.51 Million | +1.18% |
| 2023-12-31 | $249.57 Million | +84.49% |
| 2022-12-31 | $135.28 Million | -7.09% |
| 2021-12-31 | $145.60 Million | -9.35% |
| 2020-12-31 | $160.62 Million | +43.42% |
| 2019-12-31 | $112.00 Million | +121.48% |
| 2018-12-31 | $50.57 Million | +7.64% |
| 2017-12-31 | $46.98 Million | -17.05% |
| 2016-12-31 | $56.63 Million | -33.11% |
| 2015-12-31 | $84.67 Million | -10.83% |
| 2014-12-31 | $94.95 Million | +153.46% |
| 2013-12-31 | $37.46 Million | +12.10% |
| 2012-12-31 | $33.42 Million | -64.77% |
| 2011-12-31 | $94.86 Million | +396.58% |
| 2010-12-31 | $19.10 Million | +5.44% |
| 2009-12-31 | $18.12 Million | +23.92% |
| 2008-12-31 | $14.62 Million | +41.54% |
| 2007-12-31 | $10.33 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more